Avid Bioservices Welcomes Rich McAvoy as Chief Business Officer
Seasoned business and finance leader brings disciplined growth mindset to support Avid's next phase of expansion and client execution.
Avid Bioservices, a prominent contract development and manufacturing organization (CDMO) known for its CGMP manufacturing services for biopharmaceutical products, has announced a significant leadership change with the appointment of Rich McAvoy as Chief Business Officer (CBO).
Rich McAvoy is a highly respected business leader with extensive experience across various sectors, including strategic investment management, operational finance, and compliance. His expertise will be instrumental as Avid focuses on strengthening its growth and enhancing client deliverables.
New Strategies for Growth
In his new role, McAvoy will steer Avid's growth strategy, emphasizing disciplined execution and scalable operations. According to Kenneth Bilenberg, CEO of Avid Bioservices, “As Avid enters its next chapter of growth, we aim to scale the organization to enhance execution and improve the client experience.”
Leadership Impact
Bilenberg expresses confidence in McAvoy's leadership, stating that his strong reputation for cultivating disciplined organizations aligns with Avid's objectives of delivering reliable outcomes. McAvoy's ability to meld strategy with execution, while ensuring compliance and managing risk, makes him a perfect fit for Avid during this pivotal time.
Responding to Industry Challenges
McAvoy's arrival at Avid comes at a crucial moment for the biopharmaceutical industry. With many companies reevaluating their supply chain strategies in light of geopolitical uncertainties, trade barriers, and a renewed focus on domestic manufacturing, Avid is poised to play a critical role in this landscape.
“Avid has built a strong reputation for quality and delivery, and I'm excited to join the team at a time when the company has clear growth ambitions,” stated McAvoy. He emphasized that his focus will be on disciplined execution to ensure on-time delivery and an exceptional customer experience.
Commitment to Quality and Execution
As McAvoy settles into his new role, Avid Bioservices remains steadfast in its mission to help customers advance critical initiatives with reliable execution and high-quality manufacturing services. The company continues to deepen its partnerships with biopharmaceutical innovators, supporting a range of programs with agility and compliance.
About Avid Bioservices
Avid Bioservices is a global CDMO specializing in mammalian cell-culture manufacturing. With its headquarters in the U.S. and an impeccable FDA record, Avid has earned the trust of biopharmaceutical innovators worldwide. The company is recognized for its quality and ability to navigate complex global regulations.
With a wealth of experience supporting both emerging biotech firms and large pharmaceutical corporations, Avid provides comprehensive solutions from development through to commercial supply.
Avid's Impressive Milestones
Avid has reached significant milestones in its operations:
- More than 600 batches manufactured.
- Over 275 commercial batches delivered around the globe.
- 6+ approved commercial products.
- 10 successful inspections conducted by major regulatory agencies.
Frequently Asked Questions
Who is Rich McAvoy?
Rich McAvoy is the newly appointed Chief Business Officer of Avid Bioservices, bringing extensive experience in the biopharmaceutical industry.
What is Avid Bioservices known for?
Avid Bioservices specializes in contract development and manufacturing for biopharmaceutical products, focusing on high-quality CGMP manufacturing.
What is the significance of McAvoy's appointment?
His appointment is crucial for Avid as the company seeks to enhance its growth strategy and improve client delivery.
How does Avid ensure quality in its services?
Avid is recognized for its commitment to quality, navigating complex regulatory requirements effectively and providing reliable delivery to customers.
What challenges is the biopharmaceutical industry facing?
The industry is currently facing challenges including supply chain resilience, geopolitical uncertainty, and trade barriers, influencing companies to adapt their strategies.
